Mumbai, Aug 5 (IANS) Cohance Lifesciences Limited on Wednesday reported a consolidated net loss of Rs 24.1 crore for the first quarter of FY27, compared to a net profit of Rs 48.9 crore in the corresponding quarter of the previous fiscal (Q1 FY26).
The company’s revenue from operations declined 23.1 per cent year-on-year to Rs 422 crore in the April-June quarter, from Rs 549 crore in the same period last financial year, as per its stock exchange filing.
Its operating performance also weakened significantly, with EBITDA plunging 99 per cent to Rs 1.2 crore from Rs 112 crore a year ago.
Consequently, the EBITDA margin contracted sharply to 0.3 per cent from 20.4 per cent in the year-ago quarter.
Despite the weak quarterly performance, the company’s shares ended the day marginally higher. The stock closed at Rs 428.40 on the BSE, up Rs 3.50, or 0.82 per cent.
Over the last five days, the company’s shares have remained almost flat, rising by just 0.34 per cent. Over the past month, the stock has declined by 5.42 per cent. However, over the last six months, it has gained 20.07 per cent.
Hyderabad-headquartered Cohance Lifesciences is a technology-driven global Contract Development and Manufacturing Organization (CDMO) and active pharmaceutical ingredient (API) platform.
The company was formed following key corporate developments, including its merger with Suven Pharmaceuticals.
Cohance provides end-to-end lifecycle solutions across small molecules, antibody-drug conjugates (ADCs), and oligonucleotides.
Its business spans pharma CDMO services, high-value complex APIs under its API+ platform, and specialty chemicals.
The company serves global pharmaceutical innovators in more than 60 countries through multiple manufacturing facilities and specialised research and development centres.
It also has expertise in advanced modalities, including ADC payloads and oligonucleotide building blocks.
–IANS
pk
